Group 1 - The core point of the news is the performance of Shenzhen Xinlitai Pharmaceutical Co., Ltd., which saw a stock price increase of 5.06% to 60.66 CNY per share, with a total market capitalization of 67.625 billion CNY as of November 6 [1] - The company was established on November 3, 1998, and went public on September 10, 2009, focusing on the research, production, and sales of pharmaceuticals and medical devices [1] - The revenue composition of the company includes 81.69% from formulations, 8.54% from devices, 7.17% from raw materials, and 2.59% from other sources [1] Group 2 - From the perspective of fund holdings, Green Fund has a significant position in Xinlitai, with its Green Xinyue One-Year Holding Mixed A Fund (011775) holding 24,000 shares, accounting for 1.54% of the fund's net value, making it the fourth-largest holding [2] - The fund has a total scale of 57.3751 million CNY and has experienced a loss of 0.34% this year, ranking 7994 out of 8149 in its category [2] - The fund has achieved a 2% return over the past year, ranking 7399 out of 8053, and has an overall loss of 8.57% since its inception [2] Group 3 - The fund manager of Green Xinyue One-Year Holding Mixed A Fund is Li Huizhong, who has been in the position for 11 years and 115 days, with a total fund size of 233 million CNY and a best return of 70.73% during his tenure [3] - The co-manager, Wang Bigong, has been in the role for 360 days, managing a fund size of 94.1611 million CNY, with a best return of 0.82% during his tenure [3]